Antidiabetic Biosimilars Market: By Drug Class (Insulin, Biguanides, Sulfonyl Ureas, Thiazolidinediones, Di Peptidyl Peptidase (DPP)-IV Inhibitors, ?-glucosidase Inhibitos, GLP-1 Agonists, SGLT-2 Inhibitors, Others),By Disease Type (Type-I Diabetes, Type-II Diabetes), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) and Geography    

Purchase Option

$ 4400
$ 4600
$ 6900

Antidiabetic Biosimilars Market size was valued at USD x million in 2023 and is poised to grow at a CAGR of x% from 2024 - 2030. Biosimilars are biological substances that are highly similar to biologics but not identical to patented biological molecules. These are manufactured after the patent expiration of the original products. Anti-diabetic biosimilars help to control the blood glucose levels in diabetic patients. Commonly used anti-diabetic drugs include biguanides, sulfonylureas, GLP-1 receptor agonists, DPP-IV inhibitors, thiazolidinediones, and insulin among others. These are cost-effective molecules with similar potency and efficiency compared with reference biological molecules. Antidiabetics help diabetic people control their blood glucose levels. Biguanides, thiazolidinediones, DPP-IV inhibitors, -glucosidase inhibitors, sulfonylureas, insulin, and GLP-1 receptor agonists like exenatide are examples of antidiabetics. A biosimilar product is a biological product that has been approved by the FDA because it is very similar to an FDA-approved biological product called a reference product. To demonstrate that the biosimilar manufactured gives the same therapeutic benefit to patients as the reference medication, biosimilar manufacturers must generate data from lab testing and clinical testing.

Key Developments:

  • In May 2017, Sanofi received Committee for Medicinal Products for Human Use (CHMP) recommendation for approval of Insulin Lispro Biosimilar

Anti Diabetic Biosimilars Market Summary

Study Period

2024-2030

Base Year

2023

CAGR

X%

Largest Market

Asia-Pacific

Fastest Growing Market

North America
Antidiabetic Biosimilars Market Dynamics

Drivers: Increase in the prevalence of diabetic patients Patent expiries block buster drugs and promising product pipeline Government initiations to control the diabetes Restraints: High cost of R&D activities Stringent regulatory policies Complexity in development of biosimilars

Key Features of the Reports

  • The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario

Anti Diabetic Biosimilars Market Segmentation

B Drug Class
  • Insulin
  • Biguanides
  • Sulfonyl Ureas
  • Thiazolidinediones
  • Di Peptidyl Peptidase (DPP)-IV Inhibitors
  • ?-glucosidase Inhibitos
  • GLP-1 Agonists
  • Others
By Disease Type
  • Type-I Diabetes
  • Type-II Diabetes
By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Frequently Asked Questions

The anti-diabetic biosimilars market, size was valued at USD x million in 2023

The anti diabetic biosimilars market, key players are: Biocon (India) Merck Sharp & Dohme Corporation (U.S.) Boehringer Ingelheim GmbH (Germany) Eli Lilly & Co. (U.S.) Sanofi-aventis U.S. LLC (U.S.) Samsung Bioepis (Samsung BioLogics) (South Korea) Mylan N.V. (U.S.) Wockhardt (India)

The anti diabetic biosimilars market, has been classified into North America, Asia Pacific, Europe, Latin America, Middle East and Africa, and the rest of MEA.

1. Executive Summary
2. Global Anti-diabetic Biosimilars Market Introduction
2.1. Global Anti-diabetic Biosimilars Market Taxonomy
2.2. Global Anti-diabetic Biosimilars Market Definitions
2.2.1. Drug Class
2.2.2. Disease Type
2.2.3. Distribution Channel
3. Global Anti-diabetic Biosimilars Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Anti-diabetic Biosimilars Market Dynamic Factors - Impact Analysis
3.6. Global Anti-diabetic Biosimilars Market Competition Landscape
3.7. Epidemiology
4. Global Anti-diabetic Biosimilars Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030
4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Opportunity Analysis
5. Global Anti-diabetic Biosimilars Market, By Drug Class, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
5.1. Insulin
5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.3. Market Opportunity Analysis
5.2. Biguanides
5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.3. Market Opportunity Analysis
5.3. Sulfonyl Ureas
5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.3.3. Market Opportunity Analysis
5.4. Thiazolidinediones
5.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.4.3. Market Opportunity Analysis
5.5. Di Peptidyl Peptidase (DPP)-IV Inhibitors
5.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.5.3. Market Opportunity Analysis
5.6. α-glucosidase Inhibitors
5.6.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
5.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.6.3. Market Opportunity Analysis
5.7. GLP-1 Agonists
5.7.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
5.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.7.3. Market Opportunity Analysis
5.8. Others
5.8.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
5.8.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.8.3. Market Opportunity Analysis
6. Global Anti-diabetic Biosimilars Market Forecast, By Disease Type, 2019 - 2023 and Forecast, 2024 - 2030
6.1. Type-I Diabetes
6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.3. Market Opportunity Analysis
6.2. Type-II Diabetes
6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.3. Market Opportunity Analysis
7. Global Anti-diabetic Biosimilars Market Forecast, By Distribution Channel, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
7.1. Hospital Pharmacies
7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.1.3. Market Opportunity Analysis
7.2. Retail Pharmacies
7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.2.3. Market Opportunity Analysis
7.3. Online Pharmacies
7.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.3.3. Market Opportunity Analysis
8. Global Anti-diabetic Biosimilars Market Forecast, By Region, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
8.1. North America
8.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.1.3. Market Opportunity Analysis
8.2. Europe
8.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.2.3. Market Opportunity Analysis
8.3. Asia-Pacific
8.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.3.3. Market Opportunity Analysis
8.4. Latin America
8.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.4.3. Market Opportunity Analysis
8.5. Middle East and Africa
8.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.5.3. Market Opportunity Analysis
8.6. Global Anti-diabetic Biosimilars Market Opportunity Analysis Index, By Drug Class, By Disease Type, By Distribution Channel, and Region, 2024 - 2030
9. North America Anti-diabetic Biosimilars Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
9.1. Drug Class Analysis 2019 - 2023 and Forecast 2024 - 2030
9.2. Disease Type Analysis 2019 - 2023 and Forecast 2024 - 2030
9.3. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030
9.4. Country Analysis 2016 and Forecast 2024 - 2030
9.5. North America Anti-diabetic Biosimilars Market Opportunity Analysis Index, By Drug Class, By Disease Type, By Distribution Channel, and Region, 2024 - 2030
9.6. North America Anti-diabetic Biosimilars Market Dynamics – Trends
10. Europe Anti-diabetic Biosimilars Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
10.1. Drug Class Analysis 2019 - 2023 and Forecast 2024 - 2030
10.2. Disease Type Analysis 2019 - 2023 and Forecast 2024 - 2030
10.3. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030
10.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030
10.5. Europe Anti-diabetic Biosimilars Market Opportunity Analysis Index, By Drug Class, By Disease Type, By Distribution Channel, and Region, 2024 - 2030
10.6. Europe Anti-diabetic Biosimilars Market Dynamics – Trends
11. Asia-Pacific Anti-diabetic Biosimilars Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
11.1. Drug Class Analysis 2019 - 2023 and Forecast 2024 - 2030
11.2. Disease Type Analysis 2019 - 2023 and Forecast 2024 - 2030
11.3. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030
11.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030
11.5. Asia-Pacific Anti-diabetic Biosimilars Market Opportunity Analysis Index, By Drug Class, By Disease Type, By Distribution Channel, and Region, 2024 - 2030
11.6. Asia-Pacific Anti-diabetic Biosimilars Market Dynamics – Trends
12. Latin America Anti-diabetic Biosimilars Market Analysis, 2012 - 2012 - 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
12.1. Drug Class Analysis 2019 - 2023 and Forecast 2024 - 2030
12.2. Disease Type Analysis 2019 - 2023 and Forecast 2024 - 2030
12.3. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030
12.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030
12.5. Latin America Anti-diabetic Biosimilars Market Opportunity Analysis Index, By Drug Class, By Disease Type, By Distribution Channel, and Region, 2024 - 2030
12.6. Latin America Anti-diabetic Biosimilars Market Dynamics – Trends
13. Middle East and Africa Anti-diabetic Biosimilars Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
13.1. Drug Class Analysis 2019 - 2023 and Forecast 2024 - 2030
13.2. Disease Type Analysis 2019 - 2023 and Forecast 2024 - 2030
13.3. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030
13.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030
13.5. MEA Anti-diabetic Biosimilars Market Opportunity Analysis Index, By Drug Class, By Disease Type, By Distribution Channel, and Region, 2024 - 2030
13.6. MEA Anti-diabetic Biosimilars Market Dynamics – Trends
14. Competition Landscape
14.1. Strategic Dashboard of Top Market Players
14.2. Company Profiles (Introduction, Financial Analysis, Drug Class & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
14.2.1. Biocon (India)
14.2.2. Merck Sharp & Dohme Corporation (U.S.)
14.2.3. Boehringer Ingelheim GmbH (Germany)
14.2.4. Eli Lilly & Co. (U.S.)
14.2.5. Sanofi-aventis U.S. LLC (U.S.)
14.2.6. Samsung Bioepis (Samsung BioLogics) (South Korea)
14.2.7. Mylan N.V. (U.S.)
14.2.8. Wockhardt (India)
15. Research Methodology
16. Key Assumptions and Acronyms
  • Biocon (India)
  • Merck Sharp & Dohme Corporation (U.S.)
  • Boehringer Ingelheim GmbH (Germany)
  • Eli Lilly & Co. (U.S.)
  • Sanofi-aventis U.S. LLC (U.S.)
  • Samsung Bioepis (Samsung BioLogics) (South Korea)
  • Mylan N.V. (U.S.)
  • Wockhardt (India)

Adjacent Markets